3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Squamous Cell Carcinoma of Head and Neck
11
Small Cell Lung Carcinoma
11
Lung Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Hepatocellular
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Advanced Solid Tumors
7
Melanoma
6
Biliary Tract Neoplasms
6
Urinary Bladder Neoplasms
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Carcinoma, Renal Cell
4
Stomach Neoplasms
3
Recurrence
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Advanced Solid Tumours
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Solid Tumor
2
Interventions
Fluorouracil
38
Capecitabine
31
Oxaliplatin
30
Leucovorin
30
Radiotherapy
21
Irinotecan
20
Bevacizumab
15
Radiation
12
Cetuximab
12
pembrolizumab
9
Gemcitabine
7
trifluridine tipiracil drug combination
5
dehydroftorafur
5
cediranib
5
Radiotherapy, Intensity-Modulated
5
Folfox protocol
5
Erlotinib Hydrochloride
5
Cisplatin
5
Carboplatin
5
trametinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Neoadjuvant Therapy
4
Gene Expression Profiling
4
Cyclophosphamide
4
sargramostim
3
binimetinib
3
Trifluridine
3
Sorafenib
3
Pemetrexed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rectal Neoplasms
×
durvalumab
×
Clear all
NCT04108481
2025-03-28
iRE-C
University of Iowa
Phase 1
Terminated
5 enrolled